Abstract
INTRODUCTION Complex perceptual discrimination is supported by tau-vulnerable regions of the medial temporal lobe; notably the perirhinal cortex. This research tests whether there is a gene-dose effect of Apolipoprotein e4 on perceptual discrimination in mid-life.
METHODS 313 adults (45-65 years; grouped by APOE e4 gene-dose (142 APOE33, 135 APOE34, 36 APOE44)) completed a Greebles ‘odd-one-out’ task.
RESULTS APOE44 carriers were significantly less accurate in their perceptual judgements than APOE33 and APOE34 individuals. There was a significant Age x APOE e4 gene-dose interaction in response speed, with the slope of age-related slowing increasing stepwise with the number of e4 alleles carried. Estimates suggest high-risk individuals are quicker than the APOE33 control group until age 54, but slower thereafter.
DISCUSSION Perceptual disadvantages specific to APOE44 individuals suggest this high-risk group show compromised MTL-function by mid-life, potentially through accelerated tau-aggregation. Task performance in APOE34 carriers is relatively preserved across the studied age range.
Research in Context
Systematic review: A review of the literature (e.g., PubMed; Google Scholar databases) revealed perceptual discrimination is impaired in the mild to moderate stages of Alzheimer’s Disease. No prior study, however, tests for an effect of APOE e4 gene-dose in healthy adulthood.
Interpretation: Homozygous carriers of an APOE e4 genetic risk variant show perceptual disadvantages in mid-life. This may possibly reflect compromised MTL-function in this group, consistent with the theory perceptual discrimination will be vulnerable to early transentorhinal tau-accumulation. There is limited evidence of impairment in individuals carrying one copy of APOE e4 in mid-life.
Future directions: Whether transentorhinal and hippocampal tau mediates the relationship between APOE e4 gene-dose and perceptual discrimination remains to be established. Future research may also explore the utility of perceptual discrimination tasks in clinical trials targeting the preclinical stages of Alzheimer’s Disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by funding from Alzheimers Society (AS-JF-19(a)-007) to CL, Alzheimers Research UK South Coast Network pump-priming grants to CL, CB, and JR, the European Research Council (ERC) under the European Unions Horizon 2020 research and innovation programme, grant number: 819526 to C. B., and from an Alzheimers Society Doctoral Training Centre (AS-DTC-2014-003) PhD scholarship to J.D.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Science & Technology Research Ethics Committee of the University of Sussex gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email addresses: s.berens{at}sussex.ac.uk j.daly{at}sussex.ac.uk j.rusted{at}sussex.ac.uk chris.bird{at}sussex.ac.uk
Declarations of interest: None (CL, SB, JD, JR, CB).
Data Availability
Model parameter estimates and standard errors are uploaded to the project repository on the Open Science Framework, alongside anonymised trial-level datasets and scripts for running statistical models in R (https://osf.io/qns2r/).
